Significance of p85 expression as a prognostic factor for patients with breast cancer

Zhou,Weiwei; An,Guangyu; Wei,Ping; Chen,Wenming

doi:10.3892/ol.2014.2359

Significance of p85 expression as a prognostic factor for patients with breast cancer

Authors:
- Weiwei Zhou
- Guangyu An
- Ping Wei
- Wenming Chen
View Affiliations

Affiliations: Department of Oncology, Beijing Chao‑Yang Hospital, Capital Medical University, Beijing 100020, P.R. China, Department of Pathology, Beijing Chao‑Yang Hospital, Capital Medical University, Beijing 100020, P.R. China, Department of Hematology, Beijing Chao‑Yang Hospital, Capital Medical University, Beijing 100020, P.R. China
Published online on: July 18, 2014 https://doi.org/10.3892/ol.2014.2359
Pages: 1657-1661

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

p85, the regulatory subunit of phosphatidylinositol 3‑kinase (PI3K), functions in the pathogenesis and progression of human breast cancers. Previous studies have observed that p85 isoforms may correlate with cancer cell proliferation. In the present study, immunohistochemical staining of p85 was performed in 126 primary breast cancers. The association between the expression levels of p85 with clinicopathological variables, subtypes and prognosis was studied. The breast cancer specimens were divided into three subgroups according to the expression levels of p85 protein. High p85 protein expression was significantly correlated with tumor grade, vascular invasion and recurrence and/or metastasis (P<0.05). Increased p85 protein expression was associated with the human epidermal growth factor receptor 2‑positive and triple‑negative breast cancers (P=0.008). Patients with higher p85 protein expression levels showed shorter disease‑free survival and overall survival times as compared with those with lower expression levels of p85 (P<0.001). Cox proportional‑hazards analysis showed that p85 protein expression was not an independent prognostic factor. Further large‑scale studies are required to evaluate the significance of p85 protein expression as a prognostic marker for breast cancer.

View Figures

View References

1	Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase-AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002.
2	Bader AG, Kang S, Zhao L and Vogt PK: Oncogenic PI3K deregulates transcriptionand translation. Nat Rev Cancer. 5:921–929. 2005.
3	Wang SI, Puc J, Li J, et al: Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res. 57:4183–4186. 1997.
4	Sun M, Paciga JE, Feldman RI, et al: Phosphatidylinositol-3-OH-Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res. 61:5985–5991. 2001.
5	Shayesteh L, Lu Y, Kuo WL, et al: PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 21:99–102. 1999.
6	Yokoyama Y, Wan X, Shinohara A, et al: Expression of PTEN and PTEN pseudogene in endometrial carcinoma. Int J Mol Med. 6:47–50. 2000.
7	Forgacs E, Biesterveld EJ, Sekido Y, et al: Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene. 17:1557–1565. 1998.
8	Dahia PL, Marsh DJ, Zheng Z, et al: Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res. 57:4710–4713. 1997.
9	Jaiswal BS, Janakiraman V, Kljavin NM, et al: Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell. 16:463–474. 2009.
10	Sun M, Hillmann P, Hofmann BT, Hart JR and Vogt PK: Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. Proc Natl Acad Sci USA. 107:15547–15552. 2010.
11	Cortés I, Sánchez-Ruíz J, Zuluaga S, et al: p85β phosphoinositide 3-kinase subunit regulates tumor progression. Proc Natl Acad Sci USA. 109:11318–11823. 2012.
12	Taniguchi CM, Winnay J, Kondo T, et al: The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling. Cancer Res. 70:5305–5315. 2010.
13	Folgiero V, Di Carlo SE, Bon G, et al: Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells. Cell Death Dis. 3:e4402012.
14	Camp RL, Dolled-Filhart M and Rimm DL: X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 10:7252–7259. 2004.
15	Miller TW, Rexer BN, Garrett JT and Arteaga CL: Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 13:2242011.
16	NCCN clinical practice guidelines in breast cancer. 2013, version 2 http://www.nccn.org/. Accessed May 1 2013
17	Lin X, Böhle AS, Dohrmann P, et al: Overexpression of phosphatidylinositol 3-kinase in human lung cancer. Langenbecks Arch Surg. 386:293–301. 2001.
18	Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423. 2003.
19	Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
20	Zito CR, Jilaveanu LB, Anagnostou V, et al: Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells. PLoS One. 7:e313312012.